Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03646344
Other study ID # AC17065
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date March 12, 2019
Est. completion date February 23, 2021

Study information

Verified date June 2021
Source University of Edinburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Organ shortage for transplant has necessitated use of kidneys from older donors, increasing the chance that the kidney will not work immediately or for as long as expected. The investigators gave the drug heme arginate (HA) to 20 kidney transplant patients in the first 24 hours after transplant, and showed that it may reduce kidney injury and is safe. The investigators plan to conduct a large study recruiting 600 patients to determine whether HA treatment increases the number of kidney transplants that work immediately. If successful, HA may be introduced into clinical practice at the end of this study. Patients will be invited to take part in the study once listed for a kidney transplant. Further discussions will be had with them when admitted for transplant, and they will be offered the opportunity to participate. Consent will not be taken until the patient is admitted for transplantation. Following consent, participants will be randomised to receive either 2 doses of the study drug, HA, or a salt water solution, one at the time of transplant, and one approximately 24 hours later. Otherwise, treatment will be the same as any other patient undergoing a kidney transplant. Information about recovery from surgery, and specifically about kidney function, will be collected, but will not require additional blood tests. The study period ends after the first 7 days post-transplant, although longer term data will be collected from routine follow up appointments. Participants will be asked to complete a simple quality of life questionnaire 3 times: just before transplant, at approximately one week and three months after transplant.


Recruitment information / eligibility

Status Terminated
Enrollment 47
Est. completion date February 23, 2021
Est. primary completion date March 17, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients undergoing a kidney only transplant, or a dual kidney transplant, from a deceased donor - At least 18 years of age, no upper limit - Receiving standard immunosuppression for the individual centre - (where applicable) Meets co-enrolment criteria outlined in section 4.4 of the protocol Exclusion Criteria: - Kidney transplant patients as part of a multi-organ transplant e.g. with pancreas or liver - Known hypersensitivity to heme arginate - Unable to give informed consent - Patients with porphyria, irrespective of whether they have received heme arginate or not, will be excluded - Previous randomisation into this study (or HOT study) - Women who are pregnant or lactating - Kidneys that have undergone Ex-vivo Normothermic Perfusion (EVNP) - Patients with known liver disease, epilepsy, brain injury or disease

Study Design


Intervention

Drug:
Heme Arginate 25 MG/ML
IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
0.9% Sodium-chloride
Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).

Locations

Country Name City State
United Kingdom Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh Edinburgh
United Kingdom NHS Lothian - Royal Infirmary of Edinburgh Edinburgh Lothian

Sponsors (2)

Lead Sponsor Collaborator
University of Edinburgh Kidney Cancer UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other 1 Year graft survival Graft survival rates at 1 year post transplant will be obtained from routinely collected data and differences between treatment groups assessed. 1 year
Other 1 year recipient survival Recipient survival rates at 1 year post transplant will be obtained from routinely collected data and differences between treatment groups assessed. 1 year
Primary Delayed Graft Function The incidence of delayed graft function, defined as failure of a spontaneous fall in creatinine of >10% for each 3 consecutive day period in the first week following transplantation, with comparison between the two randomised groups. 1 week post transplant
Secondary Requirement for dialysis The number of participants requiring dialysis within the first week post-transplant 1 week post transplant
Secondary Time to functioning graft The number of days to functioning graft, defined as the spontaneous fall in creatinine of greater than, or equal to 10% over a period of 3 consecutive days in the first 7 days post transplant 1 week
Secondary Length of hospital stay The number of days spent in hospital, along with level of care (ward/HDU/ITU), for the index admission (transplantation admission) 3 months
Secondary Creatinine levels Serum creatinine levels at 1 and 3 months post-transplant across both randomised groups 3 months
Secondary Acute rejection The number of participants with biopsy-proven acute rejection within the first 3 months post-transplant 3 months
Secondary SF36 Quality of Life A comparison of differences between groups in patient reported quality of life using the SF36 Up to 3 months post transplant
Secondary Cost per QALY gained Using data derived from the SF36 to weight survival for quality of life, Quality Adjusted Life Year (QALY) will be assessed Up to 3 months post transplant
See also
  Status Clinical Trial Phase
Completed NCT03140514 - Urine CXCL10 Chemokine Monitoring Post-renal Transplant N/A
Completed NCT02581436 - Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR N/A
Active, not recruiting NCT02409940 - To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients Phase 1
Completed NCT02377193 - Simulect Versus ATG in Sensitized Renal Transplant Patient Phase 4
Completed NCT00771745 - Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients Phase 4
Not yet recruiting NCT05385432 - Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies Phase 3
Completed NCT01953120 - Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309) Phase 4
Terminated NCT01324934 - Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids Phase 3
Terminated NCT00983645 - A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity Phase 4
Active, not recruiting NCT04530630 - Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant Phase 4
Recruiting NCT03707262 - Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor Phase 1/Phase 2
Completed NCT02006108 - Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance N/A
Recruiting NCT03991780 - Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection Phase 1/Phase 2
Completed NCT02733029 - Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection Phase 2
Active, not recruiting NCT02057965 - Mesenchymal Stromal Cell Therapy in Renal Recipients Phase 2
Completed NCT00658073 - Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts N/A
Completed NCT02866682 - Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients Phase 4
Not yet recruiting NCT06438107 - Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
Completed NCT02500251 - Belimumab Impacting Transplant Eligibility Phase 1/Phase 2
Completed NCT00866879 - Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients Phase 4